Primary midbrain germinoma relapse-free for 5 years: A case report

Akito Oshima; Toshikazu Kimura; Atsuya Akabane; Tomohiro Inoue

doi:10.25259/SNI_703_2022

Primary midbrain germinoma relapse-free for 5 years: A case report

Surg Neurol Int. 2022 Dec 9:13:574. doi: 10.25259/SNI_703_2022. eCollection 2022.

Authors

Akito Oshima^{1

2}, Toshikazu Kimura³, Atsuya Akabane⁴, Tomohiro Inoue¹

Affiliations

¹ Department of Neurosurgery, NTT Medical Center Tokyo, Tokyo, Japan.
² Department Neurosurgery, Yokohama City University, Graduate School of Medicine, Fukuura, Kanazawa-ku, Yokohama, Japan.
³ Department of Neurosurgery, Japanese Red Cross Medical Center, Tokyo, Japan.
⁴ Gamma Knife Center, NTT Medical Center Tokyo, Tokyo, Japan.

Abstract

Background: The biology and clinical course of intracranial germinomas differ as per their location of occurrence. Germinoma of the primary midbrain is particularly rare, and its clinical features, treatment strategies, and long-term prognosis remain uncertain.

Case description: A 39-year-old man who had been diagnosed with midbrain germinoma by open biopsy through the occipital transtentorial approach had undergone chemoradiotherapy and achieved 5 years with no recurrence.

Conclusion: Germinomas should be considered as a differential diagnosis for adolescents and young adult men with mesencephalic tumors, and reliable sampling followed by chemoradiotherapy must be performed.

Keywords: Intracranial germinoma; Midbrain tumor; Occipital transtentorial approach; Radiotherapy.

Publication types

Case Reports